• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新冠肺炎合并合并症继发毛霉菌病(黑霉)——放大全球大流行的悲伤,灾难开始。

Mucormycosis (black fungus) ensuing COVID-19 and comorbidity meets - Magnifying global pandemic grieve and catastrophe begins.

机构信息

Department of Zoology, School of Biosciences, Avinashilingam Institute for Home Science and Higher Education for Women, Coimbatore 641 043, Tamil Nadu, India.

Department of Life Science, CHRIST (Deemed to be University), Bengaluru, Karnataka 560076, India.

出版信息

Sci Total Environ. 2022 Jan 20;805:150355. doi: 10.1016/j.scitotenv.2021.150355. Epub 2021 Sep 16.

DOI:10.1016/j.scitotenv.2021.150355
PMID:34818767
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8443313/
Abstract

Post COVID-19, mucormycosis occurred after the SARS-CoV-2 has rampaged the human population and is a scorching problem among the pandemic globally, particularly among Asian countries. Invasive mucormycosis has been extensively reported from mild to severe COVID-19 survivors. The robust predisposing factor seems to be uncontrolled diabetes mellitus, comorbidity and immunosuppression acquired through steroid therapy. The prime susceptive reason for the increase of mucormycosis cases is elevated iron levels in the serum of the COVID survivors. A panoramic understanding of the infection has been elucidated based on clinical manifestation, genetic and non- genetic mechanisms of steroid drug administration, biochemical pathways and immune modulated receptor associations. This review lime-lights and addresses the "What", "Why", "How" and "When" about the COVID-19 associated mucormycosis (CAM) in a comprehensive manner with a pure intention to bring about awareness to the common public as the cases are inevitably and exponentially increasing in India and global countries as well. The article also unearthed the pathogenesis of mucormycosis and its association with the COVID-19 sequela, the plausible routes of entry, diagnosis and counter remedies to keep the infection at bay. Cohorts of case reports were analysed to spotlight the link between the pandemic COVID-19 and the nightmare-mucormycosis.

摘要

新冠疫情后,由于 SARS-CoV-2 肆虐人类,侵袭性毛霉菌病已成为全球范围内的热点问题,尤其是在亚洲国家。从轻度到重度 COVID-19 幸存者中都广泛报道了侵袭性毛霉菌病。强有力的诱发因素似乎是未控制的糖尿病、合并症和通过类固醇治疗获得的免疫抑制。COVID 幸存者血清中铁水平升高是毛霉菌病病例增加的主要易感原因。基于临床表现、类固醇药物给药的遗传和非遗传机制、生化途径和免疫调节受体关联,对感染进行了全面的了解。本综述以全面的方式重点介绍了 COVID-19 相关毛霉菌病(CAM)的“是什么”、“为什么”、“如何”和“何时”,旨在引起普通公众的关注,因为印度和全球各国的病例不可避免地呈指数级增长。文章还揭示了毛霉菌病的发病机制及其与 COVID-19 后遗症的关联、可能的进入途径、诊断和防治措施,以控制感染。对病例报告进行了分析,以强调大流行 COVID-19 与噩梦般的毛霉菌病之间的联系。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c27/8443313/ec9e8d73f2e1/gr6_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c27/8443313/8915386b7623/ga1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c27/8443313/ee70062cb1f4/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c27/8443313/060cf1dc26c6/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c27/8443313/82a861953d5d/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c27/8443313/96e64b7d6980/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c27/8443313/b424540012f8/gr5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c27/8443313/ec9e8d73f2e1/gr6_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c27/8443313/8915386b7623/ga1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c27/8443313/ee70062cb1f4/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c27/8443313/060cf1dc26c6/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c27/8443313/82a861953d5d/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c27/8443313/96e64b7d6980/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c27/8443313/b424540012f8/gr5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c27/8443313/ec9e8d73f2e1/gr6_lrg.jpg

相似文献

1
Mucormycosis (black fungus) ensuing COVID-19 and comorbidity meets - Magnifying global pandemic grieve and catastrophe begins.新冠肺炎合并合并症继发毛霉菌病(黑霉)——放大全球大流行的悲伤,灾难开始。
Sci Total Environ. 2022 Jan 20;805:150355. doi: 10.1016/j.scitotenv.2021.150355. Epub 2021 Sep 16.
2
Mucormycosis, past and present: a comprehensive review.毛霉病:过去与现在——全面综述
Future Microbiol. 2023 Feb;18:217-234. doi: 10.2217/fmb-2022-0141. Epub 2023 Mar 27.
3
Covid-19 and mucormycosis (Black Fungus): An epidemic within the pandemic.Covid-19 与毛霉菌病(黑真菌):大流行中的一场疫情。
Rocz Panstw Zakl Hig. 2021;72(3):239-244. doi: 10.32394/rpzh.2021.0169.
4
Multicenter Epidemiologic Study of Coronavirus Disease-Associated Mucormycosis, India.印度冠状病毒疾病相关毛霉菌病的多中心流行病学研究。
Emerg Infect Dis. 2021 Sep;27(9):2349-2359. doi: 10.3201/eid2709.210934. Epub 2021 Jun 4.
5
Antifungal Effect of Nanoparticles against COVID-19 Linked Black Fungus: A Perspective on Biomedical Applications.纳米颗粒对与 COVID-19 相关的黑曲霉的抗真菌作用:对生物医学应用的展望。
Int J Mol Sci. 2022 Oct 19;23(20):12526. doi: 10.3390/ijms232012526.
6
Association of Serum Iron Studies in COVID Associated Mucormycosis with Stage of the Disease.血清铁研究与 COVID 相关毛霉菌病疾病阶段的相关性。
J Assoc Physicians India. 2022 Apr;70(4):11-12.
7
Mucormycosis: An opportunistic pathogen during COVID-19.毛霉菌病:COVID-19 期间的机会性病原体。
Environ Res. 2021 Oct;201:111643. doi: 10.1016/j.envres.2021.111643. Epub 2021 Jul 6.
8
The impact of mucormycosis (black fungus) on SARS-CoV-2-infected patients: at a glance.新型冠状病毒感染患者中毛霉菌病(黑霉病)的影响:一目了然。
Environ Sci Pollut Res Int. 2022 Oct;29(46):69341-69366. doi: 10.1007/s11356-022-22204-8. Epub 2022 Aug 19.
9
COVID-19 associated mucormycosis - An emerging threat.新型冠状病毒肺炎相关毛霉菌病——一种新出现的威胁。
J Microbiol Immunol Infect. 2022 Apr;55(2):183-190. doi: 10.1016/j.jmii.2021.12.007. Epub 2022 Jan 13.
10
Surge of mucormycosis during the COVID-19 pandemic.新冠疫情期间毛霉菌病的爆发。
Travel Med Infect Dis. 2023 Mar-Apr;52:102557. doi: 10.1016/j.tmaid.2023.102557. Epub 2023 Feb 20.

引用本文的文献

1
Optimizing therapeutic efficacy of antifungal peptides via strategic terminal amino acid modification.通过策略性末端氨基酸修饰优化抗真菌肽的治疗效果。
J Adv Res. 2024 Sep 23. doi: 10.1016/j.jare.2024.09.017.
2
Epidemiology, pathogenesis, clinical characteristics, and treatment of mucormycosis: a review.棘白菌素类药物在侵袭性曲霉菌病治疗中的作用。
Ann Med. 2024 Dec;56(1):2396570. doi: 10.1080/07853890.2024.2396570. Epub 2024 Sep 2.
3
The Review of Ophthalmic Symptoms in COVID-19.新型冠状病毒肺炎的眼部症状综述

本文引用的文献

1
Mucormycosis, The Deadly New Worry to COVID-19 Pandemic.毛霉菌病:新冠大流行期间新的致命威胁
Mymensingh Med J. 2021 Jul;30(3):874-880.
2
COVID-19-associated mucormycosis: An updated systematic review of literature.COVID-19 相关毛霉病:文献的更新系统评价。
Mycoses. 2021 Dec;64(12):1452-1459. doi: 10.1111/myc.13338. Epub 2021 Jun 25.
3
Rhinocerebral Mucormycosis and COVID-19 Pneumonia.鼻脑型毛霉菌病与新型冠状病毒肺炎
Clin Ophthalmol. 2024 May 23;18:1417-1432. doi: 10.2147/OPTH.S460224. eCollection 2024.
4
Mucormycosis: A Rare disease to Notifiable Disease.毛霉菌病:一种罕见但应报告的疾病。
Braz J Microbiol. 2024 Jun;55(2):1065-1081. doi: 10.1007/s42770-024-01315-z. Epub 2024 Apr 1.
5
Hyphae of and Are More Virulent and Resistant to Antifungal Agents Than Sporangiospores In Vitro and in .在体外和体内,毛霉属和根霉属的菌丝比孢子囊孢子更具毒性且对抗真菌剂更具抗性。
J Fungi (Basel). 2023 Sep 23;9(10):958. doi: 10.3390/jof9100958.
6
Hyperbaric oxygen therapy as an adjunctive treatment for COVID-19-associated mucormycosis: a report of two cases.高压氧疗法作为 COVID-19 相关毛霉菌病的辅助治疗:两例报告。
Rev Peru Med Exp Salud Publica. 2023 Jan-Mar;40(1):105-110. doi: 10.17843/rpmesp.2023.401.11980. Epub 2023 Jun 23.
7
Assessing and Reassessing the Association of Comorbidities and Coinfections in COVID-19 Patients.评估和重新评估新冠病毒肺炎患者合并症和合并感染之间的关联
Cureus. 2023 Mar 25;15(3):e36683. doi: 10.7759/cureus.36683. eCollection 2023 Mar.
8
Antimycotic effect of 3-phenyllactic acid produced by probiotic bacterial isolates against Covid-19 associated mucormycosis causing fungi.益生菌分离株产生的 3-苯乳酸对与 COVID-19 相关的毛霉菌病致病真菌的抗真菌作用。
PLoS One. 2023 Mar 30;18(3):e0279118. doi: 10.1371/journal.pone.0279118. eCollection 2023.
9
Potential Strategies to Control the Risk of Antifungal Resistance in Humans: A Comprehensive Review.控制人类抗真菌耐药性风险的潜在策略:全面综述
Antibiotics (Basel). 2023 Mar 18;12(3):608. doi: 10.3390/antibiotics12030608.
10
An Attention towards the Prophylactic and Therapeutic Options of Phytochemicals for SARS-CoV-2: A Molecular Insight.关注植物化学物质对 SARS-CoV-2 的预防和治疗选择:分子视角。
Molecules. 2023 Jan 13;28(2):795. doi: 10.3390/molecules28020795.
J Med Cases. 2021 Mar;12(3):85-89. doi: 10.14740/jmc3637. Epub 2021 Jan 19.
4
Sino-orbital mucormycosis in a COVID-19 patient: A case report.一名新冠肺炎患者的鼻窦眼眶毛霉菌病:病例报告
Int J Surg Case Rep. 2021 May;82:105957. doi: 10.1016/j.ijscr.2021.105957. Epub 2021 May 4.
5
Healthcare-associated Pediatric Cutaneous Mucormycosis at Texas Children's Hospital, 2012-2019.2012-2019 年德克萨斯儿童医疗中心发生的与医疗保健相关的儿科皮肤毛霉菌病。
Pediatr Infect Dis J. 2021 Aug 1;40(8):746-748. doi: 10.1097/INF.0000000000003153.
6
When Uncontrolled Diabetes Mellitus and Severe COVID-19 Converge: The Perfect Storm for Mucormycosis.当未控制的糖尿病与重症 COVID-19 相遇:毛霉菌病的完美风暴。
J Fungi (Basel). 2021 Apr 15;7(4):298. doi: 10.3390/jof7040298.
7
Title of the Article: Paranasal Mucormycosis in COVID-19 Patient.文章标题:新冠病毒感染患者的鼻旁窦毛霉病
Indian J Otolaryngol Head Neck Surg. 2022 Oct;74(Suppl 2):3407-3410. doi: 10.1007/s12070-021-02574-0. Epub 2021 Apr 22.
8
The role of co-infections and secondary infections in patients with COVID-19.合并感染和继发感染在新冠肺炎患者中的作用。
Pneumonia (Nathan). 2021 Apr 25;13(1):5. doi: 10.1186/s41479-021-00083-w.
9
Mucormycosis after Coronavirus disease 2019 infection in a heart transplant recipient - Case report and review of literature.COVID-19 感染后心脏移植受者发生毛霉菌病 - 病例报告及文献复习。
J Mycol Med. 2021 Jun;31(2):101125. doi: 10.1016/j.mycmed.2021.101125. Epub 2021 Apr 2.
10
Rhino-orbital mucormycosis during steroid therapy in COVID-19 patients: A case report.COVID-19 患者类固醇治疗期间发生的鼻眶脑毛霉病:一例报告。
Eur J Ophthalmol. 2022 Jul;32(4):NP11-NP16. doi: 10.1177/11206721211009450. Epub 2021 Apr 10.